An experimental drug that targets abnormally
high levels of a
protein linked to cancer growth appears to significantly reduce the proliferation of prostate cancer cells in laboratory cell cultures and
animals, while also making these cells
considerably more vulnerable to radiation, according to results of a study led by Johns Hopkins scientists.